Clinical Trials
3 trialsNCT06444880 2026-06-04
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06528769 2025-09-30
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT04873375 2024-10-31
Cemiplimab for Secondary Angiosarcomas
Radboud University Medical Center
Phase 2 Completed